Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study-Reference-Cited by-同舟云学术

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Published:2024-07-02 Issue:9 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Uittenboogaard Aniek¹²^ORCID,van de Velde Mirjam¹,van de Heijden Lisa³⁴,Mukuhi Leah⁵,de Vries Niels³,Langat Sandra⁵,Olbara Gilbert⁶^ORCID,Huitema Alwin D. R.²³⁷,Vik Terry⁸^ORCID,Kaspers Gertjan¹²,Njuguna Festus⁶

Affiliation:

1. Emma Children's Hospital, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

2. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

3. Department of Pharmacy & Pharmacology Netherlands Cancer Institute Amsterdam The Netherlands

4. Department of Clinical Pharmacy OLVG Amsterdam The Netherlands

5. Academic Model Providing Access to Healthcare (AMPATH) Eldoret Kenya

6. Department of Child Health and Paediatrics Moi University/Moi Teaching and Referral Hospital Eldoret Kenya

7. Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

8. Pediatric Hematology/Oncology Indiana University School of Medicine Indianapolis Indiana USA

Abstract

AbstractThe low incidence of vincristine‐induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose‐escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31160

Reference29 articles.

1. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review

2. Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment

3. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433

4. CYP3A5genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer

5. Outcomes of Wilms tumor treatment in western Kenya